PEPTIDEATLAS / LIBRARY
Survodutide: mechanism, Phase 3 and status
Survodutide explained: GLP-1/glucagon mechanism, the SYNCHRONIZE Phase 3 programme, current status and limits of the evidence.
Mechanism and research context
A dual receptor agonist studied in overweight and obesity. The clinical programme evaluates both efficacy and safety.
Continue reading
How to assess the evidence
Check the trial, participant population, duration and comparison. Consider adverse events and discontinuations alongside the measured effect.
Results for a combination do not automatically apply to either component alone. Separate trials are not a head-to-head comparison.
What the results do not establish
Clinical findings do not establish the composition or quality of an online shop product. This profile provides no individual treatment, dosing or use instructions.
Primary source checked: 2026-09-22. Not presented as independently medically reviewed.